← Mirum Pharmaceuticals, Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $2.2m |
$0
-100.00%
|
$19.1m |
$77.1m
+302.66%
|
$186.4m
+141.85%
|
$336.9m
+80.76%
|
$521.3m
+54.74%
|
$618.1m
+18.56%
|
|
| Loss from termination of revenue interest purchase agreement | — | — | $0 | $0 | ($49.1m) | $0 | $0 | — | |
| Cost of sales | — | $0 | $1.9m |
$12.4m
+550.24%
|
$47.0m
+280.14%
|
$81.6m
+73.56%
|
$100.2m
+22.78%
|
$113.0m
+12.68%
|
|
| Gross Profit | — | $0 | $17.2m |
$64.7m
+275.33%
|
$139.3m
+115.40%
|
$255.2m
+83.19%
|
$421.1m
+64.97%
|
$505.1m
+19.96%
|
|
| Research and development | $43.0m | $81.6m | $131.4m | $106.8m | $102.6m | $140.6m | $186.2m | $287.5m | |
| Selling, general and administrative | — | — | $59.2m | $89.1m | $145.9m | $202.2m | $257.0m | $313.8m | |
| Total operating expenses | $54.7m | $104.3m | $192.6m | $208.3m | $295.5m | $424.5m | $543.4m | $601.3m | |
| Loss from operations | ($54.7m) |
($104.3m)
-90.52%
|
($173.4m)
-66.27%
|
($131.2m)
+24.33%
|
($109.2m)
+16.82%
|
($87.6m)
+19.74%
|
($22.1m)
+74.73%
|
— | |
| Interest expense | $0 | ($335k) | ($17.6m) | ($16.0m) | ($15.1m) | ($14.3m) | ($14.4m) | $13.4m | |
| Interest income | $2.2m | $1.6m | $366k | $3.9m | $13.7m | $13.8m | $12.7m | $13.9m | |
| Other income (expense), net | ($21k) | ($192k) | ($582k) | $365k | ($2.8m) | $1.2m | $2.4m | ($761.8m) | |
| Loss before provision for income taxes | ($52.5m) | ($103.3m) | ($84.0m) | ($142.1m) | ($162.4m) | ($86.9m) | ($21.4m) | — | |
| Provision for income taxes | $21k | $6k | $37k | ($6.4m) | $991k | $1.0m | $1.9m | — | |
| Net loss | ($52.6m) | ($103.3m) | ($84.0m) | ($135.7m) | ($163.4m) | ($87.9m) | ($23.4m) | — | |
| Net loss per share, basic (in dollars per share) | — | — | ($3) | ($4) | ($4) | ($2) | ($0) | — | |
| Net loss per share, diluted (in dollars per share) | ($5) | ($4) | ($3) | ($4) | ($4) | ($2) | ($0) | — | |
| Weighted-average shares of common stock outstanding, basic (in shares) | — | — | 30.3m | 33.8m | 40.9m | 47.5m | 50.2m | 56.1m | |
| Weighted-average shares of common stock outstanding, diluted (in shares) | — | — | 30.3m | 34.0m | 40.9m | 47.5m | 50.2m | 56.1m |